ArticleSurgical case reports2026
Pathological Complete Response after Surgery following Chemotherapy with Immune Checkpoint Inhibitors for Gastric Cancer with Liver Metastases: Two Case Reports.
Article in Surgical case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionIn recent years, advances in pharmacotherapy, including the introduction of immune checkpoint inhibitors (ICIs), have affected treatment strategies for advanced gastric cancer. Surgical intervention after systemic therapy has the potential to improve the prognosis of patients with advanced gastric cancer and liver metastases. Herein, we report two cases in which gastrectomy and hepatectomy were performed after pharmacotherapy with ICIs, resulting in a pathological complete response. CASE PRESENTATION: Case 1 was a 75-year-old man diagnosed with gastric cancer causing stenosis from the antrum to the duodenal bulb. Contrast-enhanced CT revealed a 3.2 cm liver metastasis with a tumor thrombus in the right portal and posterior sectoral branches. The patient was diagnosed with cT4aN+M1(HEP) Stage IVB gastric cancer and received four courses of S-1 plus oxaliplatin (SOX) and nivolumab. Marked tumor shrinkage led to surgery, including distal gastrectomy and posterior segmentectomy. Pathological examination revealed no residual tumor in the primary or liver lesions, with a histological grade 3 response. Postoperatively, S-1 and nivolumab were initiated, and the patient remained recurrence-free for 5 months. Case 2 was a 77-year-old man who was diagnosed with gastric cancer during screening. Contrast-enhanced CT revealed a 2.2 cm liver metastasis in segment 8. A diagnosis of cT4aN+M1(HEP) stage IVB disease was made, and he received four courses of SOX and nivolumab preoperatively. After tumor shrinkage, total gastrectomy and S8 partial hepatectomy were performed. Pathological examination revealed no residual tumor in the primary or liver lesions, with a histological grade 3 response. Postoperatively, S-1 and nivolumab were initiated, and the patient remained recurrence-free for 6 months.
conclusionsCurative resection following pharmacotherapy with ICIs may represent a potential treatment strategy for gastric cancer with liver metastases. Further case reports are required to evaluate the safety and long-term outcomes of surgery following systemic therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.